Campedel Luca, Kossaï Myriam, Blanc-Durand Paul, Rouprêt Morgan, Seisen Thomas, Compérat Eva, Spano Jean-Philippe, Malouf Gabriel
AP-HP, université Pierre-et-Marie-Curie (Paris-VI), groupe hospitalier Pitié-Salpêtrière, institut universitaire de cancérologie, département d'oncologie médicale, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
Université Paris-Sud, Gustave-Roussy, département de pathologie, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
Bull Cancer. 2017 Sep;104(9):789-799. doi: 10.1016/j.bulcan.2017.05.007. Epub 2017 Jun 30.
Neuroendocrine prostate cancer is a rare malignancy with a an adverse prognostic. Histologically, It can be pure (small cells or large cells neuroendocrine carcinoma) or mixed with a adenocarcinoma component. Rarely diagnosed de novo, neuroendocrine prostate cancer is generally associated with advanced stage disease resistant to castration. As such, this histological subtype could represent an aggressive evolution of prostatic adenocarcinoma, through the epithelio-neuroendocrine transdifferentiation mechanism (phenomenon of lineage plasticity). Nonetheless, neuroendocrine prostate cancer is a heterogeneous malignancy with multiple histopathological variants showing distinct clinical features. The broad variety of molecular analyses could help to understand the ontogeny of this histological subtype and its signaling pathways. This may also allow identifying diagnostic and prognostic biomarkers as well as potential molecular targets. However, treatment options are currently limited and consist only in platinium-based chemotherapy for advanced stage disease.
神经内分泌前列腺癌是一种预后不良的罕见恶性肿瘤。从组织学上看，它可以是纯的（小细胞或大细胞神经内分泌癌），也可以与腺癌成分混合。神经内分泌前列腺癌很少初发时就被诊断出来，通常与晚期去势抵抗性疾病相关。因此，这种组织学亚型可能代表前列腺腺癌通过上皮-神经内分泌转分化机制（谱系可塑性现象）的侵袭性演变。尽管如此，神经内分泌前列腺癌是一种异质性恶性肿瘤，有多种组织病理学变异，表现出不同的临床特征。广泛的分子分析有助于了解这种组织学亚型的发生及其信号通路。这也可能有助于识别诊断和预后生物标志物以及潜在的分子靶点。然而，目前治疗选择有限，仅包括针对晚期疾病的铂类化疗。
